Last reviewed · How we verify
Kogenate FS
At a glance
| Generic name | Kogenate FS |
|---|---|
| Sponsor | Octapharma |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (NA)
- Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
- Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A (PHASE2)
- Weight-based Dosing in Hemophilia A (PHASE2)
- Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients
- Canadian Hemophilia Prophylaxis Study (PHASE4)
- Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A (PHASE2)
- Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kogenate FS CI brief — competitive landscape report
- Kogenate FS updates RSS · CI watch RSS
- Octapharma portfolio CI